1
|
Zhao B, Peng H, Zhang Y, Zhang J, Kong D, Cao S, Li Y, Yang D, Sun C, Pu X, Zhao P, Xu Y, Zhao K, Xie L. Rapid development and mass production of SARS-CoV-2 neutralizing chicken egg yolk antibodies with protective efficacy in hamsters. Biol Res 2024; 57:24. [PMID: 38711133 DOI: 10.1186/s40659-024-00508-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2023] [Accepted: 04/25/2024] [Indexed: 05/08/2024] Open
Abstract
Despite the record speed of developing vaccines and therapeutics against the SARS-CoV-2 virus, it is not a given that such success can be secured in future pandemics. In addition, COVID-19 vaccination and application of therapeutics remain low in developing countries. Rapid and low cost mass production of antiviral IgY antibodies could be an attractive alternative or complementary option for vaccine and therapeutic development. In this article, we rapidly produced SARS-CoV-2 antigens, immunized hens and purified IgY antibodies in 2 months after the SARS-CoV-2 gene sequence became public. We further demonstrated that the IgY antibodies competitively block RBD binding to ACE2, neutralize authentic SARS-CoV-2 virus and effectively protect hamsters from SARS-CoV-2 challenge by preventing weight loss and lung pathology, representing the first comprehensive study with IgY antibodies. The process of mass production can be easily implemented in most developing countries and hence could become a new vital option in our toolbox for combating viral pandemics. This study could stimulate further studies, optimization and potential applications of IgY antibodies as therapeutics and prophylactics for human and animals.
Collapse
Affiliation(s)
- Binan Zhao
- Shanghai Bio-full Biotech Co.,Ltd, Shanghai, 201106, China
| | - Haoran Peng
- Department of Microbiology, Second Military Medical University, Shanghai, 200433, China
| | - Yanjing Zhang
- Sinocelltech Ltd, No.31 Kechuang 7th Street, BDA, Beijing, 100176, China
| | - Jie Zhang
- Beijing Antibody Research Key Laboratory, Sino Biological Inc, Building 9, Jing DongBei Technology Park, No.18 Ke Chuang 10th St, BDA, Beijing, 100176, China
| | - Desheng Kong
- Sinocelltech Ltd, No.31 Kechuang 7th Street, BDA, Beijing, 100176, China
| | - Sai Cao
- Sinocelltech Ltd, No.31 Kechuang 7th Street, BDA, Beijing, 100176, China
- Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd, No.31 Kechuang 7th Street, BDA, Beijing, 100176, China
| | - Yan Li
- Beijing Antibody Research Key Laboratory, Sino Biological Inc, Building 9, Jing DongBei Technology Park, No.18 Ke Chuang 10th St, BDA, Beijing, 100176, China
| | - Dan Yang
- College of Life Sciences, Shanghai Normal University, Shanghai, 200234, China
| | - Chuanwen Sun
- College of Life Sciences, Shanghai Normal University, Shanghai, 200234, China
| | - Xinyi Pu
- College of Life Sciences, Shanghai Normal University, Shanghai, 200234, China
| | - Ping Zhao
- Department of Microbiology, Second Military Medical University, Shanghai, 200433, China
| | - Yan Xu
- College of Life Sciences, Shanghai Normal University, Shanghai, 200234, China
| | - Kai Zhao
- Shanghai Bio-full Biotech Co.,Ltd, Shanghai, 201106, China.
| | - Liangzhi Xie
- Sinocelltech Ltd, No.31 Kechuang 7th Street, BDA, Beijing, 100176, China.
- Beijing Antibody Research Key Laboratory, Sino Biological Inc, Building 9, Jing DongBei Technology Park, No.18 Ke Chuang 10th St, BDA, Beijing, 100176, China.
- Beijing Engineering Research Center of Protein and Antibody, Sinocelltech Ltd, No.31 Kechuang 7th Street, BDA, Beijing, 100176, China.
- Cell Culture Engineering Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100005, China.
| |
Collapse
|
2
|
Zhang Y, Pham HM, Tran SD. The Chicken Egg: An Advanced Material for Tissue Engineering. Biomolecules 2024; 14:439. [PMID: 38672456 PMCID: PMC11048217 DOI: 10.3390/biom14040439] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2024] [Revised: 03/28/2024] [Accepted: 03/31/2024] [Indexed: 04/28/2024] Open
Abstract
The chicken egg, an excellent natural source of proteins, has been an overlooked native biomaterial with remarkable physicochemical, structural, and biological properties. Recently, with significant advances in biomedical engineering, particularly in the development of 3D in vitro platforms, chicken egg materials have increasingly been investigated as biomaterials due to their distinct advantages such as their low cost, availability, easy handling, gelling ability, bioactivity, and provision of a developmentally stimulating environment for cells. In addition, the chicken egg and its by-products can improve tissue engraftment and stimulate angiogenesis, making it particularly attractive for wound healing and tissue engineering applications. Evidence suggests that the egg white (EW), egg yolk (EY), and eggshell membrane (ESM) are great biomaterial candidates for tissue engineering, as their protein composition resembles mammalian extracellular matrix proteins, ideal for cellular attachment, cellular differentiation, proliferation, and survivability. Moreover, eggshell (ES) is considered an excellent calcium resource for generating hydroxyapatite (HA), making it a promising biomaterial for bone regeneration. This review will provide researchers with a concise yet comprehensive understanding of the chicken egg structure, composition, and associated bioactive molecules in each component and introduce up-to-date tissue engineering applications of chicken eggs as biomaterials.
Collapse
Affiliation(s)
- Yuli Zhang
- Faculty of Dental Medicine and Oral Health Sciences, McGill University, 3640 University Street, Montreal, QC H3A 0C7, Canada; (Y.Z.); (H.M.P.)
| | - Hieu M. Pham
- Faculty of Dental Medicine and Oral Health Sciences, McGill University, 3640 University Street, Montreal, QC H3A 0C7, Canada; (Y.Z.); (H.M.P.)
- Department of Periodontology, Eastman Institute for Oral Health, University of Rochester Medical Center, 625 Elmwood Avenue, Rochester, NY 14620, USA
| | - Simon D. Tran
- Faculty of Dental Medicine and Oral Health Sciences, McGill University, 3640 University Street, Montreal, QC H3A 0C7, Canada; (Y.Z.); (H.M.P.)
| |
Collapse
|
3
|
Zhang D, Kukkar D, Kim KH, Bhatt P. A comprehensive review on immunogen and immune-response proteins of SARS-CoV-2 and their applications in prevention, diagnosis, and treatment of COVID-19. Int J Biol Macromol 2024; 259:129284. [PMID: 38211928 DOI: 10.1016/j.ijbiomac.2024.129284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2023] [Revised: 01/03/2024] [Accepted: 01/04/2024] [Indexed: 01/13/2024]
Abstract
Exposure to severe acute respiratory syndrome-corona virus-2 (SARS-CoV-2) prompts humoral immune responses in the human body. As the auxiliary diagnosis of a current infection, the existence of viral proteins can be checked from specific antibodies (Abs) induced by immunogenic viral proteins. For people with a weakened immune system, Ab treatment can help neutralize viral antigens to resist and treat the disease. On the other hand, highly immunogenic viral proteins can serve as effective markers for detecting prior infections. Additionally, the identification of viral particles or the presence of antibodies may help establish an immune defense against the virus. These immunogenic proteins rather than SARS-CoV-2 can be given to uninfected people as a vaccination to improve their coping ability against COVID-19 through the generation of memory plasma cells. In this work, we review immunogenic and immune-response proteins derived from SARS-CoV-2 with regard to their classification, origin, and diverse applications (e.g., prevention (vaccine development), diagnostic testing, and treatment (via neutralizing Abs)). Finally, advanced immunization strategies against COVID-19 are discussed along with the contemporary circumstances and future challenges.
Collapse
Affiliation(s)
- Daohong Zhang
- College of Food Engineering, Ludong University, Yantai 264025, Shandong, China; Bio-Nanotechnology Research Institute, Ludong University, Yantai 264025, Shandong, China
| | - Deepak Kukkar
- Department of Biotechnology, Chandigarh University, Gharuan, Mohali 140413, Punjab, India; University Center for Research and Development, Chandigarh University, Gharuan, Mohali 140413, Punjab, India
| | - Ki-Hyun Kim
- Department of Civil & Environmental Engineering, Hanyang University, 222 Wangsimni-Ro, Seoul 04763, Republic of Korea.
| | - Poornima Bhatt
- Department of Biotechnology, Chandigarh University, Gharuan, Mohali 140413, Punjab, India; University Center for Research and Development, Chandigarh University, Gharuan, Mohali 140413, Punjab, India
| |
Collapse
|
4
|
Ahmadi TS, Behrouz B, Mousavi Gargari SL. Polyclonal anti-whole cell IgY passive immunotherapy shields against P. aeruginosa-induced acute pneumonia and burn wound infections in murine models. Sci Rep 2024; 14:405. [PMID: 38172232 PMCID: PMC10764880 DOI: 10.1038/s41598-023-50859-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2023] [Accepted: 12/27/2023] [Indexed: 01/05/2024] Open
Abstract
Pseudomonas aeruginosa (PA) is a multidrug-resistant (MDR) opportunistic pathogen causing severe hospital-, and community-acquired infections worldwide. Thus, the development of effective immunotherapy-based treatments is essential to combat the MDR-PA infections. In the current study, we evaluated the protective efficacy of polyclonal avian antibodies raised against inactivated whole cells of the PAO1 strain in murine models of acute pneumonia and burn wound. The efficacy of generated antibodies was evaluated against different PA strains through several in vitro, ex vivo and in vivo experiments. The results showed that the anti-PAO1-IgY effectively reduced the motility, biofilm formation and cell internalization ability, and enhanced the opsonophagocytic killing of PA strains through the formation of immobilized bacteria and induction of increased cell surface hydrophobicity. Furthermore, immunotherapy with anti-PAO1-IgY completely protected mice against all PA strains in both acute pneumonia and burn wound murine models. It was found to reduce the bacterial loads in infected burned mice through interfering with virulence factors that play vital roles in the early stages of PA infection, such as colonization and cell internalization. The immunotherapy with anti-PAO1-IgYs could be instrumental in developing effective therapies aimed at reducing the morbidity and mortality associated with PA infections.
Collapse
Affiliation(s)
- Tooba Sadat Ahmadi
- Department of Biology, Faculty of Basic Sciences, Shahed University, Tehran-Qom Express Way, Tehran, 3319118651, Iran
| | - Bahador Behrouz
- Department of Biology, Faculty of Basic Sciences, Shahed University, Tehran-Qom Express Way, Tehran, 3319118651, Iran
| | - Seyed Latif Mousavi Gargari
- Department of Biology, Faculty of Basic Sciences, Shahed University, Tehran-Qom Express Way, Tehran, 3319118651, Iran.
| |
Collapse
|
5
|
Wang H, Zhong Q, Lin J. Egg Yolk Antibody for Passive Immunization: Status, Challenges, and Prospects. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 2023; 71:5053-5061. [PMID: 36960586 DOI: 10.1021/acs.jafc.2c09180] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/18/2023]
Abstract
The immunoglobulin Y (IgY) derived from hyperimmune egg yolk is a promising passive immune agent to combat microbial infections in humans and livestock. Numerous studies have been performed to develop specific egg yolk IgY for pathogen control, but with limited success. To date, the efficacy of commercial IgY products, which are all delivered through an oral route, has not been approved or endorsed by any regulatory authorities. Several challenging issues of the IgY-based passive immunization, which were not fully recognized and holistically discussed in previous publications, have impeded the development of effective egg yolk IgY products for humans and animals. This review summarizes major challenges of this technology, including in vivo stability, purification, heterologous immunogenicity, and repertoire diversity of egg yolk IgY. To tackle these challenges, potential solutions, such as encapsulation technologies to stabilize IgY, are discussed. Exploration of this technology to combat the COVID-19 pandemic is also updated in this review.
Collapse
Affiliation(s)
- Huiwen Wang
- Department of Animal Science, The University of Tennessee, Knoxville, Tennessee 37996, United States
| | - Qixin Zhong
- Department of Food Science, The University of Tennessee, Knoxville, Tennessee 37996, United States
| | - Jun Lin
- Department of Animal Science, The University of Tennessee, Knoxville, Tennessee 37996, United States
| |
Collapse
|
6
|
cKMT1 is a new lysine methyltransferase that methylates the ferredoxin-NADP(+) oxidoreductase (FNR) and regulates energy transfer in cyanobacteria. Mol Cell Proteomics 2023; 22:100521. [PMID: 36858286 PMCID: PMC10090440 DOI: 10.1016/j.mcpro.2023.100521] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2022] [Revised: 02/20/2023] [Accepted: 02/24/2023] [Indexed: 03/03/2023] Open
Abstract
Lysine methylation is a conserved and dynamic regulatory post-translational modification performed by lysine methyltransferases (KMTs). KMTs catalyze the transfer of mono-, di-, or tri-methyl groups to substrate proteins and play a critical regulatory role in all domains of life. To date, only one KMT has been identified in cyanobacteria. Here, we tested all of the predicted KMTs in the cyanobacterium Synechocystis sp. PCC 6803 (Synechocystis), and we biochemically characterized sll1526 that we termed cKMT1 (cyanobacterial lysine methyltransferase 1), and determined that it can catalyze lysine methylation both in vivo and in vitro. Loss of cKMT1 alters photosynthetic electron transfer in Synechocystis. We analyzed cKMT1-regulated methylation sites in Synechocystis using a timsTOF Pro instrument. We identified 305 class I lysine methylation sites within 232 proteins, and of these, 80 methylation sites in 58 proteins were hypomethylated in ΔcKMT1 cells. We further demonstrated that cKMT1 could methylate ferredoxin-NADP(+) oxidoreductase (FNR) and its potential sites of action on FNR were identified. Amino acid residues H118 and Y219 were identified as key residues in the putative active site of cKMT1 as indicated by structure simulation, site-directed mutagenesis, and KMT activity measurement. Using mutations that mimic the unmethylated forms of FNR, we demonstrated that the inability to methylate K139 residues results in a decrease in the redox activity of FNR and affects energy transfer in Synechocystis. Together, our study identified a new KMT in Synechocystis and elucidated a methylation-mediated molecular mechanism catalyzed by cKMT1 for the regulation of energy transfer in cyanobacteria.
Collapse
|
7
|
Gu L, Liu Y, Zhang W, Li J, Chang C, Su Y, Yang Y. Novel extraction technologies and potential applications of egg yolk proteins. Food Sci Biotechnol 2022; 32:121-133. [PMID: 36590017 PMCID: PMC9795146 DOI: 10.1007/s10068-022-01209-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2022] [Revised: 11/07/2022] [Accepted: 11/14/2022] [Indexed: 12/29/2022] Open
Abstract
The high nutritional value and diverse functional properties of egg yolk proteins have led to its widespread use in the fields of food, medicine, and cosmetics. Various extraction methods have been reported to obtain the proteins from egg yolk, however, their utilization is limited due to the relatively low extraction efficiency and/or toxic solvents involved. Several simpler and greener technologies, especially physical fields (ultrasound), have been successfully developed to improve the extraction efficiency. The egg yolk proteins may exert multiple biological activities, enabling them to be a promising tool in improve human health and wellbeing, such as anti-obesity, anti-atherosclerosis, anti-osteoporosis, diagnosis and therapy for SARS-CoV-2 infections. This article summarizes the novel extraction technologies and latest applications of the egg yolk proteins in the recent 5 years, which should stimulate their utilization as health-promoting functional ingredients in foods and other commercial products.
Collapse
Affiliation(s)
- Luping Gu
- State Key Laboratory of Food Science and TechnologySchool of Food Science and TechnologyCollaborative Innovation Center of Food Safety and Quality Control in Jiangsu Province, Jiangnan University, Wuxi, 214122 China ,Hunan Engineering & Technology Research Center for Food Flavors and Flavorings, Jinshi, 415400 Hunan China
| | - Yufang Liu
- College of Food Engineering and Nutritional Science, Shanxi Normal University, Xi’an, China
| | - Wanqiu Zhang
- State Key Laboratory of Food Science and TechnologySchool of Food Science and TechnologyCollaborative Innovation Center of Food Safety and Quality Control in Jiangsu Province, Jiangnan University, Wuxi, 214122 China
| | - Junhua Li
- State Key Laboratory of Food Science and TechnologySchool of Food Science and TechnologyCollaborative Innovation Center of Food Safety and Quality Control in Jiangsu Province, Jiangnan University, Wuxi, 214122 China
| | - Cuihua Chang
- State Key Laboratory of Food Science and TechnologySchool of Food Science and TechnologyCollaborative Innovation Center of Food Safety and Quality Control in Jiangsu Province, Jiangnan University, Wuxi, 214122 China
| | - Yujie Su
- State Key Laboratory of Food Science and TechnologySchool of Food Science and TechnologyCollaborative Innovation Center of Food Safety and Quality Control in Jiangsu Province, Jiangnan University, Wuxi, 214122 China ,Hunan Engineering & Technology Research Center for Food Flavors and Flavorings, Jinshi, 415400 Hunan China
| | - Yanjun Yang
- State Key Laboratory of Food Science and TechnologySchool of Food Science and TechnologyCollaborative Innovation Center of Food Safety and Quality Control in Jiangsu Province, Jiangnan University, Wuxi, 214122 China ,Hunan Engineering & Technology Research Center for Food Flavors and Flavorings, Jinshi, 415400 Hunan China
| |
Collapse
|
8
|
Zhang M, Zhang L, Yang J, Zhao D, Han K, Huang X, Liu Q, Xiao Y, Gu Y, Li Y. An IgY Effectively Prevents Goslings from Virulent GAstV Infection. Vaccines (Basel) 2022; 10:vaccines10122090. [PMID: 36560500 PMCID: PMC9781778 DOI: 10.3390/vaccines10122090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2022] [Revised: 11/28/2022] [Accepted: 12/05/2022] [Indexed: 12/14/2022] Open
Abstract
Goose astrovirus (GAstV) leads to viscera and joints urate deposition in 1- to 20-day-old goslings, with a mortality rate of up to 50%, posing a severe threat to entire colonies; however, there is no efficient prevention and control method for GAstV infection. This study describes a prophylactic anti-GAstV strategy based on the specific immunoglobulin Y (IgY) from egg yolk. The specific IgY was produced by 22-week-old laying hens intramuscularly immunized with the inactivated GAstV three consecutive times, with 2-week intervals. The egg yolk was collected weekly after the immunization and the anti-GAstV IgY titer was monitored using an agar gel immune diffusion assay (AGID). The results revealed that the AGID titer began to increase on day 7, reached a peak on day 49, and remained at a high level until day 77 after the first immunization. The specific IgY was prepared from the combinations of egg yolk from day 49 to day 77 through PEG-6000 precipitation. Animal experiments were conducted to evaluate the effects of prevention and treatment. The result of the minimum prophylactic dose of the IgY showed that the protection rate was 90.9% when 2.5 mg was administrated. Results of the prevention and the treatment experiments showed prevention and cure rates of over 80% when yolk antibody was administered in the early stages of the GAstV infection. These results suggested that the specific IgY obtained from immunized hens with the inactivated GAstV could be a novel strategy for preventing and treating GAstV infection.
Collapse
Affiliation(s)
- Mengran Zhang
- College of Animal Science, Anhui Science and Technology University, Fengyang 233100, China
- Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Science, Nanjing 210014, China
- Key Laboratory of Veterinary Biological Engineering and Technology, Ministry of Agriculture, Nanjing 210014, China
| | - Lijiao Zhang
- Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Science, Nanjing 210014, China
- Key Laboratory of Veterinary Biological Engineering and Technology, Ministry of Agriculture, Nanjing 210014, China
| | - Jing Yang
- Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Science, Nanjing 210014, China
- Key Laboratory of Veterinary Biological Engineering and Technology, Ministry of Agriculture, Nanjing 210014, China
| | - Dongmin Zhao
- Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Science, Nanjing 210014, China
- Key Laboratory of Veterinary Biological Engineering and Technology, Ministry of Agriculture, Nanjing 210014, China
| | - Kaikai Han
- Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Science, Nanjing 210014, China
- Key Laboratory of Veterinary Biological Engineering and Technology, Ministry of Agriculture, Nanjing 210014, China
| | - Xinmei Huang
- Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Science, Nanjing 210014, China
- Key Laboratory of Veterinary Biological Engineering and Technology, Ministry of Agriculture, Nanjing 210014, China
| | - Qingtao Liu
- Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Science, Nanjing 210014, China
- Key Laboratory of Veterinary Biological Engineering and Technology, Ministry of Agriculture, Nanjing 210014, China
| | - Yichen Xiao
- Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Science, Nanjing 210014, China
- Key Laboratory of Veterinary Biological Engineering and Technology, Ministry of Agriculture, Nanjing 210014, China
| | - Youfang Gu
- College of Animal Science, Anhui Science and Technology University, Fengyang 233100, China
| | - Yin Li
- Institute of Veterinary Medicine, Jiangsu Academy of Agricultural Science, Nanjing 210014, China
- Key Laboratory of Veterinary Biological Engineering and Technology, Ministry of Agriculture, Nanjing 210014, China
- Correspondence:
| |
Collapse
|
9
|
Eka Saputri M, Aisyah Rahmalia Effendi S, Nadila R, Azzam Fajar S, Damajanti Soejoedono R, Handharyani E, Nadia Poetri O. Immunoglobulin yolk targeting spike 1, receptor binding domain of spike glycoprotein and nucleocapsid of SARS-CoV-2 blocking RBD-ACE2 binding interaction. Int Immunopharmacol 2022; 112:109280. [PMID: 36183680 PMCID: PMC9515349 DOI: 10.1016/j.intimp.2022.109280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2022] [Revised: 09/13/2022] [Accepted: 09/22/2022] [Indexed: 11/16/2022]
Abstract
Coronavirus disease (COVID)-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become a global pandemic disease that has social and economic chaos. An alternative mitigation strategy may involve the use of specific immunoglobulin (Ig)-Y derived from chicken eggs. Our study aimed to evaluate the neutralizing potential of specific IgY targeting S1, receptor-binding-domain (RBD) of spike glycoprotein and nucleocapsid (N) of SARS-CoV-2 to inhibit RBD and angiotensin-converting-enzyme-2 (ACE2) binding interaction. Hy-Line Brown laying hens were immunized with recombinant S1, RBD spike glycoprotein, and nucleocapsid (N) of SARS-CoV-2. The presence of specific S1,RBD,N-IgY in serum and egg yolk was verified by indirect enzyme-linked immunosorbent assay (ELISA). Specific S1,RBD,N-IgY was purified and characterized from egg yolk using sodium-dodecyl-sulfate-polyacrylamide-gel-electrophoresis (SDS-PAGE), and was subsequently evaluated for inhibition of the RBD-ACE2 binding interaction in vitro. Specific IgY was present in serum at 1 week post–initial immunization (p.i.i), whereas its present in egg yolk was confirmed at 4 weeks p.i.i. Specific S1,RBD,N-IgY in serum was able to inhibit RBD-ACE2 binding interaction between 4 and 15 weeks p.i.i. The results of the SDS-PAGE revealed the presence of bands with molecular weights of 180 kDa, indicating the presence of whole IgY. Our results demonstrated that S1,RBD,N-IgY was able to inhibit RBD-ACE2 binding interaction in vitro, suggesting its potential use in blocking virus entry. Our study also demonstrated proof-of-concept that laying hens were able to produce this specific IgY, which could block the viral binding and large production of this specific IgY is feasible.
Collapse
Affiliation(s)
- Meliana Eka Saputri
- Study Programme of Medical Microbiology, IPB Postgraduate School, IPB University, Jl Agatis, Kampus IPB Dramaga, Bogor 16680, Indonesia
| | - Siti Aisyah Rahmalia Effendi
- Study Programme of Veterinary Medicine, School of Veterinary Medicine and Biomedical Science, IPB University, Jl Agatis, Kampus IPB Dramaga, Bogor 16680, Indonesia
| | - Rifa Nadila
- Study Programme of Veterinary Medicine, School of Veterinary Medicine and Biomedical Science, IPB University, Jl Agatis, Kampus IPB Dramaga, Bogor 16680, Indonesia
| | - Syauqi Azzam Fajar
- Study Programme of Veterinary Medicine, School of Veterinary Medicine and Biomedical Science, IPB University, Jl Agatis, Kampus IPB Dramaga, Bogor 16680, Indonesia
| | - Retno Damajanti Soejoedono
- Division of Medical Microbiology, School of Veterinary Medicine and Biomedical Science, IPB University, Jl Agatis, Kampus IPB Dramaga, Bogor 16680, Indonesia
| | - Ekowati Handharyani
- Division of Veterinary Pathology, School of Veterinary Medicine and Biomedical Science, IPB University, Jl Agatis, Kampus IPB Dramaga, Bogor 16680, Indonesia
| | - Okti Nadia Poetri
- Division of Medical Microbiology, School of Veterinary Medicine and Biomedical Science, IPB University, Jl Agatis, Kampus IPB Dramaga, Bogor 16680, Indonesia.
| |
Collapse
|
10
|
IgY Antibodies as Biotherapeutics in Biomedicine. Antibodies (Basel) 2022; 11:antib11040062. [PMID: 36278615 PMCID: PMC9590010 DOI: 10.3390/antib11040062] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2022] [Revised: 09/05/2022] [Accepted: 09/27/2022] [Indexed: 11/17/2022] Open
Abstract
Since the discovery of antibodies by Emil Von Behring and Shibasaburo Kitasato during the 19th century, their potential for use as biotechnological reagents has been exploited in different fields, such as basic and applied research, diagnosis, and the treatment of multiple diseases. Antibodies are relatively easy to obtain from any species with an adaptive immune system, but birds are animals characterized by relatively easy care and maintenance. In addition, the antibodies they produce can be purified from the egg yolk, allowing a system for obtaining them without performing invasive practices, which favors the three “rs” of animal care in experimentation, i.e., replacing, reducing, and refining. In this work, we carry out a brief descriptive review of the most outstanding characteristics of so-called “IgY technology” and the use of IgY antibodies from birds for basic experimentation, diagnosis, and treatment of human beings and animals.
Collapse
|
11
|
Ravlo E, Evensen L, Sanson G, Hildonen S, Ianevski A, Skjervold PO, Ji P, Wang W, Kaarbø M, Kaynova GD, Kainov DE, Bjørås M. Antiviral Immunoglobulins of Chicken Egg Yolk for Potential Prevention of SARS-CoV-2 Infection. Viruses 2022; 14:v14102121. [PMID: 36298676 PMCID: PMC9609661 DOI: 10.3390/v14102121] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2022] [Revised: 09/21/2022] [Accepted: 09/23/2022] [Indexed: 12/16/2022] Open
Abstract
Background: Some viruses cause outbreaks, which require immediate attention. Neutralizing antibodies could be developed for viral outbreak management. However, the development of monoclonal antibodies is often long, laborious, and unprofitable. Here, we report the development of chicken polyclonal neutralizing antibodies against SARS-CoV-2 infection. Methods: Layers were immunized twice with 14-day intervals using the purified receptor-binding domain (RBD) of the S protein of SARS-CoV-2/Wuhan or SARS-CoV-2/Omicron. Eggs were harvested 14 days after the second immunization. Polyclonal IgY antibodies were extracted. Binding of anti-RBD IgYs was analyzed by immunoblot and indirect ELISA. Furthermore, the neutralization capacity of anti-RBD IgYs was measured in Vero-E6 cells infected with SARS-CoV-2-mCherry/Wuhan and SARS-CoV-2/Omicron using fluorescence and/or cell viability assays. In addition, the effect of IgYs on the expression of SARS-CoV-2 and host cytokine genes in the lungs of Syrian Golden hamsters was examined using qRT-PCR. Results: Anti-RBD IgYs efficiently bound viral RBDs in situ, neutralized the virus variants in vitro, and lowered viral RNA amplification, with minimal alteration of virus-mediated immune gene expression in vivo. Conclusions: Altogether, our results indicate that chicken polyclonal IgYs can be attractive targets for further pre-clinical and clinical development for the rapid management of outbreaks of emerging and re-emerging viruses.
Collapse
Affiliation(s)
- Erlend Ravlo
- Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, 7028 Trondheim, Norway
- Correspondence: (E.R.); (M.B.); Tel.: +47-73598474 (M.B.)
| | - Lasse Evensen
- Norimun AS, Felleskjøpet Agri SA, Postboks 469, 0105 Oslo, Norway
| | - Gorm Sanson
- Felleskjøpet Fôrutvikling AS, Nedre Ila 20, 7018 Trondheim, Norway
| | - Siri Hildonen
- Norimun AS, Felleskjøpet Agri SA, Postboks 469, 0105 Oslo, Norway
| | - Aleksandr Ianevski
- Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, 7028 Trondheim, Norway
| | | | - Ping Ji
- Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, 7028 Trondheim, Norway
| | - Wei Wang
- Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, 7028 Trondheim, Norway
| | - Mari Kaarbø
- Department of Microbiology, Oslo University Hospital, 0105 Oslo, Norway
| | | | - Denis E. Kainov
- Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, 7028 Trondheim, Norway
- Institute of Technology, University of Tartu, 50411 Tartu, Estonia
- Institute for Molecular Medicine Finland, University of Helsinki, 00014 Helsinki, Finland
| | - Magnar Bjørås
- Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, 7028 Trondheim, Norway
- Correspondence: (E.R.); (M.B.); Tel.: +47-73598474 (M.B.)
| |
Collapse
|
12
|
Agurto-Arteaga A, Poma-Acevedo A, Rios-Matos D, Choque-Guevara R, Montesinos-Millán R, Montalván Á, Isasi-Rivas G, Cauna-Orocollo Y, Cauti-Mendoza MDG, Pérez-Martínez N, Gutierrez-Manchay K, Ramirez-Ortiz I, Núñez-Fernández D, Salguedo-Bohorquez MI, Quiñones-Garcia S, Fernández Díaz M, Guevara Sarmiento LA, Zimic M. Preclinical Assessment of IgY Antibodies Against Recombinant SARS-CoV-2 RBD Protein for Prophylaxis and Post-Infection Treatment of COVID-19. Front Immunol 2022; 13:881604. [PMID: 35664008 PMCID: PMC9157249 DOI: 10.3389/fimmu.2022.881604] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Accepted: 04/04/2022] [Indexed: 12/21/2022] Open
Abstract
Within the framework of the current COVID-19 pandemic, there is a race against time to find therapies for the outbreak to be controlled. Since vaccines are still tedious to develop and partially available for low-income countries, passive immunity based on egg-yolk antibodies (IgY) is presented as a suitable approach to preclude potential death of infected patients, based on its high specificity/avidity/production yield, cost-effective manufacture, and ease of administration. In the present study, IgY antibodies against a recombinant RBD protein of SARS-CoV-2 were produced in specific-pathogen-free chickens and purified from eggs using a biocompatible method. In vitro immunoreactivity was tested, finding high recognition and neutralization values. Safety was also demonstrated prior to efficacy evaluation, in which body weight, kinematics, and histopathological assessments of hamsters challenged with SARS-CoV-2 were performed, showing a protective effect administering IgY intranasally both as a prophylactic treatment or a post-infection treatment. The results of this study showed that intranasally delivered IgY has the potential to both aid in prevention and in overcoming COVID-19 infection, which should be very useful to control the advance of the current pandemic and the associated mortality.
Collapse
Affiliation(s)
- Andres Agurto-Arteaga
- Laboratorio de Biotecnología Molecular y Genómica, Laboratorios de Investigación y Desarrollo, Farmacológicos Veterinarios SAC (FARVET SAC), Chincha, Peru
| | - Astrid Poma-Acevedo
- Laboratorio de Biotecnología Molecular y Genómica, Laboratorios de Investigación y Desarrollo, Farmacológicos Veterinarios SAC (FARVET SAC), Chincha, Peru
| | - Dora Rios-Matos
- Laboratorio de Biotecnología Molecular y Genómica, Laboratorios de Investigación y Desarrollo, Farmacológicos Veterinarios SAC (FARVET SAC), Chincha, Peru
| | - Ricardo Choque-Guevara
- Laboratorio de Biotecnología Molecular y Genómica, Laboratorios de Investigación y Desarrollo, Farmacológicos Veterinarios SAC (FARVET SAC), Chincha, Peru
| | - Ricardo Montesinos-Millán
- Laboratorio de Biotecnología Molecular y Genómica, Laboratorios de Investigación y Desarrollo, Farmacológicos Veterinarios SAC (FARVET SAC), Chincha, Peru
| | - Ángela Montalván
- Laboratorio de Biotecnología Molecular y Genómica, Laboratorios de Investigación y Desarrollo, Farmacológicos Veterinarios SAC (FARVET SAC), Chincha, Peru
| | - Gisela Isasi-Rivas
- Laboratorio de Biotecnología Molecular y Genómica, Laboratorios de Investigación y Desarrollo, Farmacológicos Veterinarios SAC (FARVET SAC), Chincha, Peru
| | - Yudith Cauna-Orocollo
- Laboratorio de Bioinformática, Biología Molecular y Desarrollos Tecnológicos, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Peru
| | - María de Grecia Cauti-Mendoza
- Laboratorio de Bioinformática, Biología Molecular y Desarrollos Tecnológicos, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Peru
| | - Norma Pérez-Martínez
- Laboratorio de Biotecnología Molecular y Genómica, Laboratorios de Investigación y Desarrollo, Farmacológicos Veterinarios SAC (FARVET SAC), Chincha, Peru
| | - Kristel Gutierrez-Manchay
- Laboratorio de Biotecnología Molecular y Genómica, Laboratorios de Investigación y Desarrollo, Farmacológicos Veterinarios SAC (FARVET SAC), Chincha, Peru
| | - Ingrid Ramirez-Ortiz
- Laboratorio de Biotecnología Molecular y Genómica, Laboratorios de Investigación y Desarrollo, Farmacológicos Veterinarios SAC (FARVET SAC), Chincha, Peru
| | - Dennis Núñez-Fernández
- Laboratorio de Bioinformática, Biología Molecular y Desarrollos Tecnológicos, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Peru
| | - Mario I Salguedo-Bohorquez
- Laboratorio de Bioinformática, Biología Molecular y Desarrollos Tecnológicos, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Peru
| | - Stefany Quiñones-Garcia
- Laboratorio de Bioinformática, Biología Molecular y Desarrollos Tecnológicos, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Peru
| | - Manolo Fernández Díaz
- Laboratorio de Biotecnología Molecular y Genómica, Laboratorios de Investigación y Desarrollo, Farmacológicos Veterinarios SAC (FARVET SAC), Chincha, Peru
| | - Luis A Guevara Sarmiento
- Laboratorio de Biotecnología Molecular y Genómica, Laboratorios de Investigación y Desarrollo, Farmacológicos Veterinarios SAC (FARVET SAC), Chincha, Peru
| | - Mirko Zimic
- Laboratorio de Biotecnología Molecular y Genómica, Laboratorios de Investigación y Desarrollo, Farmacológicos Veterinarios SAC (FARVET SAC), Chincha, Peru.,Laboratorio de Bioinformática, Biología Molecular y Desarrollos Tecnológicos, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Peru
| | | |
Collapse
|
13
|
Frumkin LR, Lucas M, Scribner CL, Ortega-Heinly N, Rogers J, Yin G, Hallam TJ, Yam A, Bedard K, Begley R, Cohen CA, Badger CV, Abbasi SA, Dye JM, McMillan B, Wallach M, Bricker TL, Joshi A, Boon ACM, Pokhrel S, Kraemer BR, Lee L, Kargotich S, Agochiya M, John TS, Mochly-Rosen D. Egg-Derived Anti-SARS-CoV-2 Immunoglobulin Y (IgY) With Broad Variant Activity as Intranasal Prophylaxis Against COVID-19. Front Immunol 2022; 13:899617. [PMID: 35720389 PMCID: PMC9199392 DOI: 10.3389/fimmu.2022.899617] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2022] [Accepted: 05/03/2022] [Indexed: 01/17/2023] Open
Abstract
COVID-19 emergency use authorizations and approvals for vaccines were achieved in record time. However, there remains a need to develop additional safe, effective, easy-to-produce, and inexpensive prevention to reduce the risk of acquiring SARS-CoV-2 infection. This need is due to difficulties in vaccine manufacturing and distribution, vaccine hesitancy, and, critically, the increased prevalence of SARS-CoV-2 variants with greater contagiousness or reduced sensitivity to immunity. Antibodies from eggs of hens (immunoglobulin Y; IgY) that were administered the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein were developed for use as nasal drops to capture the virus on the nasal mucosa. Although initially raised against the 2019 novel coronavirus index strain (2019-nCoV), these anti-SARS-CoV-2 RBD IgY surprisingly had indistinguishable enzyme-linked immunosorbent assay binding against variants of concern that have emerged, including Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2), and Omicron (B.1.1.529). This is different from sera of immunized or convalescent patients. Culture neutralization titers against available Alpha, Beta, and Delta were also indistinguishable from the index SARS-CoV-2 strain. Efforts to develop these IgY for clinical use demonstrated that the intranasal anti-SARS-CoV-2 RBD IgY preparation showed no binding (cross-reactivity) to a variety of human tissues and had an excellent safety profile in rats following 28-day intranasal delivery of the formulated IgY. A double-blind, randomized, placebo-controlled phase 1 study evaluating single-ascending and multiple doses of anti-SARS-CoV-2 RBD IgY administered intranasally for 14 days in 48 healthy adults also demonstrated an excellent safety and tolerability profile, and no evidence of systemic absorption. As these antiviral IgY have broad selectivity against many variants of concern, are fast to produce, and are a low-cost product, their use as prophylaxis to reduce SARS-CoV-2 viral transmission warrants further evaluation. Clinical Trial Registration https://www.clinicaltrials.gov/ct2/show/NCT04567810, identifier NCT04567810.
Collapse
Affiliation(s)
- Lyn R. Frumkin
- School of Medicine, SPARK at Stanford, Stanford University, Stanford, CA, United States
| | - Michaela Lucas
- Faculty of Health and Medical Sciences Internal Medicine, The University of Western Australia, Perth, WA, Australia
| | | | | | - Jayden Rogers
- Linear Clinical Research Ltd, Nedlands, WA, Australia
| | - Gang Yin
- Sutro Biopharma Inc., South San Francisco, CA, United States
| | | | - Alice Yam
- Sutro Biopharma Inc., South San Francisco, CA, United States
| | - Kristin Bedard
- Sutro Biopharma Inc., South San Francisco, CA, United States
| | - Rebecca Begley
- School of Medicine, SPARK at Stanford, Stanford University, Stanford, CA, United States
| | - Courtney A. Cohen
- Virology Division, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD, United States
- The Geneva Foundation, Tacoma, WA, United States
| | - Catherine V. Badger
- Virology Division, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD, United States
| | - Shawn A. Abbasi
- Virology Division, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD, United States
| | - John M. Dye
- Virology Division, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD, United States
| | | | - Michael Wallach
- University of Technology Sydney, Sydney, NSW, Australia
- SPARK Sydney, Sydney, NSW, Australia
| | - Traci L. Bricker
- Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States
| | - Astha Joshi
- Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States
| | - Adrianus C. M. Boon
- Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States
| | - Suman Pokhrel
- Department of Chemical and Systems Biology, Stanford University, School of Medicine, Stanford, CA, United States
| | - Benjamin R. Kraemer
- Department of Chemical and Systems Biology, Stanford University, School of Medicine, Stanford, CA, United States
| | - Lucia Lee
- Department of Chemical and Systems Biology, Stanford University, School of Medicine, Stanford, CA, United States
| | - Stephen Kargotich
- School of Medicine, SPARK Global, Stanford University, Stanford, CA, United States
| | - Mahima Agochiya
- School of Medicine, SPARK at Stanford, Stanford University, Stanford, CA, United States
| | - Tom St. John
- School of Medicine, SPARK at Stanford, Stanford University, Stanford, CA, United States
| | - Daria Mochly-Rosen
- School of Medicine, SPARK at Stanford, Stanford University, Stanford, CA, United States
- Department of Chemical and Systems Biology, Stanford University, School of Medicine, Stanford, CA, United States
- School of Medicine, SPARK Global, Stanford University, Stanford, CA, United States
| |
Collapse
|
14
|
Merkuleva IA, Shcherbakov DN, Borgoyakova MB, Isaeva AA, Nesmeyanova VS, Volkova NV, Aripov VS, Shanshin DV, Karpenko LI, Belenkaya SV, Kazachinskaia EI, Volosnikova EA, Esina TI, Sergeev AA, Titova KA, Konyakhina YV, Zaykovskaya AV, Pyankov OV, Kolosova EA, Viktorina OE, Shelemba AA, Rudometov AP, Ilyichev AA. Are Hamsters a Suitable Model for Evaluating the Immunogenicity of RBD-Based Anti-COVID-19 Subunit Vaccines? Viruses 2022; 14:v14051060. [PMID: 35632800 PMCID: PMC9146860 DOI: 10.3390/v14051060] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2022] [Revised: 05/07/2022] [Accepted: 05/13/2022] [Indexed: 02/01/2023] Open
Abstract
Currently, SARS-CoV-2 spike receptor-binding-domain (RBD)-based vaccines are considered one of the most effective weapons against COVID-19. During the first step of assessing vaccine immunogenicity, a mouse model is often used. In this paper, we tested the use of five experimental animals (mice, hamsters, rabbits, ferrets, and chickens) for RBD immunogenicity assessments. The humoral immune response was evaluated by ELISA and virus-neutralization assays. The data obtained show hamsters to be the least suitable candidates for RBD immunogenicity testing and, hence, assessing the protective efficacy of RBD-based vaccines.
Collapse
Affiliation(s)
- Iuliia A. Merkuleva
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Dmitry N. Shcherbakov
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
- Correspondence: ; Tel.: +7-383-363-47-00 (ext. 2007)
| | - Mariya B. Borgoyakova
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Anastasiya A. Isaeva
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Valentina S. Nesmeyanova
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Natalia V. Volkova
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Vazirbek S. Aripov
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Daniil V. Shanshin
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Larisa I. Karpenko
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Svetlana V. Belenkaya
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Elena I. Kazachinskaia
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Ekaterina A. Volosnikova
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Tatiana I. Esina
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Alexandr A. Sergeev
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Kseniia A. Titova
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Yulia V. Konyakhina
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Anna V. Zaykovskaya
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Oleg V. Pyankov
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Evgeniia A. Kolosova
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
- Russian-American Anti-Cancer Center, Altai State University, 656049 Barnaul, Russia;
| | - Olesya E. Viktorina
- Russian-American Anti-Cancer Center, Altai State University, 656049 Barnaul, Russia;
| | - Arseniya A. Shelemba
- Federal Research Center of Fundamental and Translational Medicine, 630060 Novosibirsk, Russia;
| | - Andrey P. Rudometov
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Alexander A. Ilyichev
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| |
Collapse
|
15
|
Chen CJ, Hudson AF, Jia AS, Kunchur CR, Song AJ, Tran E, Fisher CJ, Zanchi D, Lee L, Kargotich S, Romeo M, Koperniku A, Pamnani RD, Mochly-Rosen D. Affordable IgY-based antiviral prophylaxis for resource-limited settings to address epidemic and pandemic risks. J Glob Health 2022; 12:05009. [PMID: 35265332 PMCID: PMC8877785 DOI: 10.7189/jogh.12.05009] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Background The COVID-19 pandemic caused by SARS-CoV-2 exposed a global problem, as highly effective vaccines are challenging to produce and distribute, particularly in regions with limited resources and funding. As an alternative, immunoglobulins produced in eggs of immunized hens (IgY) can be a simple and inexpensive source for a topical and temporary prophylaxis. Here, we developed a method to extract and purify IgY antibodies from egg yolks of hens immunized against viral pathogen-derived proteins using low-cost, readily available materials, for use in resource-limited settings. Methods Existing protocols for IgY purification and equipment were modified, including extraction from yolks and separation of water-soluble IgY using common household reagents and tools. A replacement for a commercial centrifuge was developed, using a home food processor equipped with a 3D printed adapter to enable IgY precipitation. IgY purification was verified using standard gel electrophoresis and Western blot analyses. Results We developed a step-by-step protocol for IgY purification for two settings in low- and middle-income countries (LMIC): a local laboratory, where commercial centrifuges are available, or a more rural setting, where an alternative for expensive centrifuges can be used. Gel electrophoresis and Western blot analyses confirmed that the method produced highly enriched IgY preparation; each commercial egg produced ~ 90 mg of IgY. We also designed a kit for IgY production in these two settings and provided a cost estimate of the kit. Conclusion IgY purified from eggs of immunized local hens can offer a fast and affordable prophylaxis, provided that purification can be performed in a resource-limited setting. Here, we created a low-cost method that can be used anywhere where electricity is available using inexpensive, readily available materials in place of costly, specialized laboratory equipment and chemicals. This procedure can readily be used now to make an anti-SARS-CoV-2 prophylaxis in areas where vaccines are unavailable, and can be modified to combat future threats from viral epidemics and pandemics.
Collapse
Affiliation(s)
- Carrie J Chen
- Office of the Vice Provost for Undergraduate Education, Stanford University, Stanford, California, USA
| | - Anna F Hudson
- Office of the Vice Provost for Undergraduate Education, Stanford University, Stanford, California, USA
| | - Allison S Jia
- Office of the Vice Provost for Undergraduate Education, Stanford University, Stanford, California, USA
| | - Caitlin R Kunchur
- Office of the Vice Provost for Undergraduate Education, Stanford University, Stanford, California, USA
| | - Andrew J Song
- Office of the Vice Provost for Undergraduate Education, Stanford University, Stanford, California, USA
| | - Edward Tran
- Office of the Vice Provost for Undergraduate Education, Stanford University, Stanford, California, USA
| | - Chris J Fisher
- Department of Comparative Medicine, Stanford University School of Medicine, Stanford, California, USA
| | - Davide Zanchi
- Graduate School of Business, Stanford University, Stanford, California, USA
| | - Lucia Lee
- Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, California, USA
| | - Stephen Kargotich
- SPARK at Stanford, Stanford University School of Medicine, Stanford, California, USA
| | - Mary Romeo
- SPARK at Stanford, Stanford University School of Medicine, Stanford, California, USA
| | - Ana Koperniku
- Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, California, USA
| | - Ravinder D Pamnani
- Stanford Byers Center for Biodesign, Stanford University, Stanford, California, USA
| | - Daria Mochly-Rosen
- Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, California, USA
- SPARK at Stanford, Stanford University School of Medicine, Stanford, California, USA
| |
Collapse
|
16
|
Ge S, Wu R, Zhou T, Liu X, Zhu J, Zhang X. Specific anti-SARS-CoV-2 S1 IgY-scFv is a promising tool for recognition of the virus. AMB Express 2022; 12:18. [PMID: 35150368 PMCID: PMC8840941 DOI: 10.1186/s13568-022-01355-4] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2021] [Accepted: 01/26/2022] [Indexed: 11/10/2022] Open
Abstract
As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread globally, a series of vaccines, antibodies and drugs have been developed to combat coronavirus disease 2019 (COVID-19). High specific antibodies are powerful tool for the development of immunoassay and providing passive immunotherapy against SARS-CoV-2 and expected with large scale production. SARS-CoV-2 S1 protein was expressed in E. coli BL21 and purified by immobilized metal affinity chromatography, as antigen used to immunize hens, the specific IgY antibodies were extracted form egg yolk by PEG-6000 precipitation, and the titer of anti-S1 IgY antibody reached 1:10,000. IgY single chain variable fragment antibody (IgY-scFv) was generated by using phage display technology and the IgY-scFv showed high binding sensitivity and capacity to S1 protein of SARS-CoV-2, and the minimum detectable antigen S1 protein concentration was 6 ng/µL. The docking study showed that the multiple epitopes on the IgY-scFv interacted with multiple residues on SARS-CoV-2 S1 RBD to form hydrogen bonds. This preliminary study suggests that IgY and IgY-scFv are suitable candidates for the development of immunoassay and passive immunotherapy for COVID-19 to humans and animals.
Collapse
|